RxDoctor Payments Data

Gnana Sunderam, MD

Internal Medicine · East Orange, NJNPI 1164446761

Payments from drug & device makers

$32,943in general payments, 2019–2025

Across 127 payments — averaging $259.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$20K
  • GSK$11K
  • Dexcom, Inc.$1K
  • AstraZeneca$324
  • Sanofi-aventis U.S. LLC$163
  • Bayer$68
  • plus $293 from 9 others

What the payments were for

  • Speaking & faculty fees$29,73090%
  • Travel & lodging$3651%
  • Food & beverage$2,8489%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,943 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$254,204
Medicare patients
190
Services billed
2,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter89$90,372
EnbrelEtanercept11$87,731
JardianceEmpagliflozin153$63,205
EliquisApixaban143$55,286
BiktarvyBictegrav/Emtricit/Tenofov Ala12$50,494
FarxigaDapagliflozin Propanediol69$34,824
XareltoRivaroxaban80$24,644
Fluticasone-SalmeterolFluticasone Propion/Salmeterol133$21,377
TrulicityDulaglutide21$17,894
TradjentaLinagliptin30$16,448
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$13,253
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$10,802
Albuterol Sulfate HfaAlbuterol Sulfate324$10,331
SymbicortBudesonide/Formoterol Fumarate21$9,057
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$8,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$11,172$99,091104 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$19,730$90,455206 claims
AmgenEnbrel$30$87,73111 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$324$57,134110 claims
Lilly USA, LLCTrulicity$56$17,89421 claims
AbbVieCombigan$41$3,98418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in East Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →